ACE2 and COVID-19: To illustrate the broad screening capability of the S3-ACE2 assay, neutralizing antibody titers against the 2019-CoV and three spike protein variants were measured in sera from 59 patients with COVID-19 who were hospitalized with (n = 31) or without (n = 28) need for intensive care unit (ICU) admission (Fig. 5).